Department of Pulmonary and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, P.R. China.
Department of Thoracic surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, P.R. China.
Diagn Pathol. 2024 Apr 19;19(1):61. doi: 10.1186/s13000-024-01486-1.
EBUS-TBNA has emerged as an important minimally invasive procedure for the diagnosis and staging of lung cancer. Our objective was to evaluate the effect of different specimen preparation from aspirates on the diagnosis of lung cancer.
181 consecutive patients with known or suspected lung cancer accompanied by hilar / mediastinal lymphadenopathy underwent EBUS-TBNA from January 2019 to December 2022. Specimens obtained by EBUS-TBNA were processed by three methods: Traditional smear cytology of aspirates (TSC), liquid-based cytology of aspirates (LBC) and histopathology of core biopsies.
EBUS-TBNA was performed in 181 patients on 213 lymph nodes, the total positive rate of the combination of three specimen preparation methods was 80.7%. The diagnostic positive rate of histopathology was 72.3%, TSC was 68.1%, and LBC was 65.3%, no significant differences was observed (p = 0.29); however, statistically significant difference was noted between the combination of three preparation methods and any single specimen preparation methods (p = 0.002). The diagnostic sensitivity of histopathology combined with TSC and histopathology combined with LBC were 96.5 and 94.8%, the specificity was 95.0% and 97.5%, the PPV was 98.8% and 99.4%, the NPV was 86.4% and 81.2%, the diagnostic accuracy was 96.2% and 95.3%, respectively; The sensitivity and accuracy of above methods were higher than that of single specimen preparation, but lower than that of combination of three preparation methods.
When EBUS-TBNA is used for the diagnosis and staging of lung cancer, histopathology combined with TSC can achieve enough diagnostic efficiency and better cost-effectiveness.
EBUS-TBNA 已成为诊断和分期肺癌的重要微创手段。本研究旨在评估不同抽吸物标本制备方法对肺癌诊断的影响。
2019 年 1 月至 2022 年 12 月,对 181 例已知或疑似肺癌伴肺门/纵隔淋巴结肿大的患者进行 EBUS-TBNA。通过 EBUS-TBNA 获得的标本通过三种方法进行处理:传统抽吸涂片细胞学(TSC)、抽吸液基细胞学(LBC)和核心活检的组织病理学。
在 181 例患者的 213 个淋巴结中进行了 EBUS-TBNA,三种标本制备方法联合的总阳性率为 80.7%。组织病理学的诊断阳性率为 72.3%,TSC 为 68.1%,LBC 为 65.3%,差异无统计学意义(p=0.29);然而,三种标本制备方法联合与任何单一标本制备方法之间存在显著差异(p=0.002)。组织病理学联合 TSC 和组织病理学联合 LBC 的诊断敏感性分别为 96.5%和 94.8%,特异性分别为 95.0%和 97.5%,PPV 分别为 98.8%和 99.4%,NPV 分别为 86.4%和 81.2%,诊断准确性分别为 96.2%和 95.3%;以上方法的敏感性和准确性均高于单一标本制备方法,但低于三种标本制备方法联合。
在 EBUS-TBNA 用于肺癌的诊断和分期时,组织病理学联合 TSC 可达到足够的诊断效率和更好的成本效益。